中山医诺维申

Inovision Pharma is a clinical-stage biotechnology company headquartered in Zhongshan, China, specializing in the discovery and development of innovative small molecule therapeutics. The company leverages a proprietary structure-based drug design platform to target high-value biological pathways in oncology and metabolic diseases. Its lead clinical candidate, INV-1120, is a selective EP4 antagonist being evaluated for the treatment of various solid tumors. Another key program, INV-1008, is a potent URAT1 inhibitor currently in Phase 2 trials for gout and hyperuricemia. Inovision is led by a team of industry veterans and is backed by prominent investors including Qiming Venture Partners and TF Capital. The company maintains operations in China and the United States to facilitate global clinical development.